Loading clinical trials...
Loading clinical trials...
A Phase 2A, Randomized, Double-blind, Placebo-controlled, Single Dose, Sequential Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 With Ticagrelor Pretreatment in Older and Elderly Subjects and With High-Dose Ticagrelor Pretreatment in Healthy Younger Subjects
Conditions
Interventions
PB2452 Infusion
Placebo - Sodium Chloride
+5 more
Locations
1
United States
PPD
Austin, Texas, United States
Start Date
April 16, 2019
Primary Completion Date
October 9, 2019
Completion Date
October 9, 2019
Last Updated
May 1, 2024
NCT07470866
NCT00104325
NCT06637865
NCT07221448
NCT07388667
NCT07118891
Lead Sponsor
SFJ Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions